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Abstract
AIM: To study whether the glucocorticoid receptor (GR/
NR3C1 ) gene haplotypes influence the steroid therapy 
outcome in inflammatory bowel disease (IBD).
METHODS: We sequenced all coding exons and flank-
ing intronic sequences of the NR3C1  gene in 181 IBD 
patients, determined the single nucleotide polymor-
phisms, and predicted the NR3C1  haplotypes. Further-
more, we investigated whether certain NR3C1  haplo-
types are significantly associated with steroid therapy 
outcomes.
RESULTS: We detected 13 NR3C1  variants, which 
led to the formation of 17 different haplotypes with a 
certainty of > 95% in 173 individuals. The three most 
commonly occurring haplotypes were included in the 
association analysis of the influence of haplotype on 
steroid therapy outcome or IBD activity. None of the 
NR3C1  haplotypes showed statistically significant as-
sociation with glucocorticoid therapy success. 
CONCLUSION: NR3C1  haplotypes are not related to 
steroid therapy outcome. 
© 2010 Baishideng. All rights reserved.
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INTRODUCTION
Inflammatory bowel diseases (IBD), Crohn’s disease (CD) 
and ulcerative colitis (UC), are multifactorial disorders, 
which are characterized by chronic recurrent inflammation 
of  the gastrointestinal tract[1]. The molecular pathogenesis 
of  IBD is not fully elucidated, although an exaggerated 
mucosal immune response triggered by intestinal bacteria 
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in genetically susceptible individuals appears to play an 
important role[2]. The combined prevalence of  CD and 
UC is estimated to be 100 to 200 per 100 000 individuals 
in developed countries[3]. IBD shows extensive variation 
in individual clinical presentation and outcomes, which is 
likely to be caused by differences in genetic susceptibility, 
environmental factors, intestinal bacteria and activation of  
the intestinal immune system[3]. 
Although great advances have been made in the man-
agement and therapy of  IBD, curative therapy does not 
yet exist. The anti-inflammatory agents mesalazine (5-ami-
nosalicylic acid, 5-ASA) and sulfasalazine, in combination 
with glucocorticoids (GCs), are common first line therapy 
options in induction and maintenance of  UC remission. 
Severe cases of  UC are treated intravenously with GCs or 
cyclosporine. CD is mainly treated with GCs and/or anti-
biotics, and azathioprine (AZA), 6-mercaptopurine (6-MP), 
or the anti-folate methotrexate (MTX) are often added to 
maintain the state of  remission[4]. GC-resistant or -depen-
dent disease courses can be treated with anti-TNF-α anti-
bodies, such as infliximab and adalimumab. GCs are often 
used in the initial treatment of  most cases of  moderate to 
severe active UC or CD. However, 20% of  patients devel-
op GC resistance within one year of  treatment[5,6]. Non-
response to GCs often leads to the need for a surgical 
intervention as a result of  a poor therapy outcome. For 
example, it has been reported that 38% and 29% of  ste-
roid-resistant CD and UC patients, respectively, required 
surgery within one year after beginning GC treatment[5].
Glucocorticoids are potent inhibitors of  T cell activa-
tion and cytokine secretion, primarily via binding to the 
cytoplasmically located glucocorticoid receptor (GR) as 
ligands. Due to ligand binding, homodimers consisting 
of  two activated GRs are formed that translocate into the 
nucleus. The complex subsequently binds to specific gluco-
corticoid response elements (GREs) within the regulatory 
regions of  GR target genes[7]. The mechanisms by which 
GC resistance develops, are not fully understood. Three 
possible mechanisms have been proposed. First, decreased 
plasma levels of  GCs through overexpression of  the drug 
efflux system P-glycoprotein (MDR1). Second, an altered 
function of  GR or, third, excessive synthesis of  pro-inflam-
matory cytokines induced by activation of  pro-inflammato-
ry transcription factors may reduce the affinity of  GR to its 
ligands and lead to the development of  GC resistance[4].
GR is known to be expressed as several polymorphic 
variants[8]. Several mutations in the NR3C1 gene have been 
found to modulate individual GC sensitivity in in vitro in-
vestigations and in studies with healthy individuals[9,10]. In 
the present study we evaluated the association between the 
NR3C1 gene haplotypes and therapeutic outcome of  GC 
administration in a well-sized cohort of  181 patients with 
IBD. The aim was to comprehensively determine abun-
dant GR variants by sequencing all protein-coding NR3C1 
exons (exons 2 to 9) and the first 50 bp of  the neighbour-
ing intronic regions in all individuals. We hypothesized that 
NR3C1 gene polymorphisms may influence GC sensitivity 
and thus might serve as predictive markers for treatment 
success with GCs in IBD patients.
MATERIALS AND METHODS
Patients
One hundred and eighty-five clinically diagnosed Swiss 
IBD patients were recruited at the centers participating 
in the Swiss Inflammatory Bowel Disease Cohort Study 
(SIBDCS)[11]. All patients gave their informed consent for 
inclusion into the study. An ethical approval was obtained 
from the Medical Ethical Committees of  the University 
Hospital Lausanne, Switzerland, and all local study sites. 
All patients had been treated with steroids and past ste-
roid therapy outcome had been recorded. The standard 
employed criteria for the steroid therapy success or failure 
are available on the website www.epact.ch. Briefly, an in-
sufficient response upon appropriate treatment in terms 
of  doses and duration was considered a steroid therapy 
failure. EDTA-blood samples were stored at the central 
tissue repository at the Institute of  Pathology, University 
of  Bern, Switzerland. The SIBDCS data center at the Uni-
versity Hospital of  Lausanne, Switzerland, provided data 
on past and current disease characteristics and GC therapy 
outcome. Diagnosis of  IBD (CD or UC) was confirmed 
by the study investigators based on clinical presentation, 
endoscopic findings and histology. 
Sequencing reactions 
DNA was extracted from EDTA-blood using the QIAcube 
robotic workstation and a standard procedure (QIAamp 
DNA Mini Kit, QIAGEN, Switzerland). The PCR and se-
quencing primer design was based on the NCBI reference 
sequence (GenBank accession number NT_029289). Prim-
ers for genomic DNA were designed to span all expressed 
exons (2 to 9) and at least 50 bp of  flanking intronic se-
quences at both 5’- and 3’-ends. The DNA sequences of  
purified PCR fragments were obtained with an ABI 3730xl 
sequencing machine. Details of  the PCR primers can be 
found in the Table 1. Optimized PCR conditions, and 
methods used for subsequent purification and sequencing 
of  the fragments are available upon request. 
 
Haplotype analysis
The PHASE software was used to calculate the hap-
lotypes based on the detected single nucleotide poly-
morphisms (SNPs) and mutations in the NR3C1 gene. 
PHASE predicts in silico haplotypes on the basis of  a 
Bayesian inference algorithm[12,13]. Haplotype calculations 
were performed on 181 individuals, from which sequence 
data of  adequate quality were obtained. To allow referral 
to specific haplotypes, a frequency-based priority criterion 
was used to name them (e.g. GR_1 for the most often oc-
curring haplotype, Table 2).
Calculation of linkage disequilibria
Linkage disequilibria (LD) were calculated using the r2 
statistics. Calculations were performed using the soft-
ware package Haploview (www.haploview.com). 
Statistical analysis
To detect differences in haplotype distribution between 
3889 August 21, 2010|Volume 16|Issue 31|WJG|www.wjgnet.com
groups with different GC therapy outcomes, the Chi-Square 
test or the Fisher’s exact test was used. It was analyzed 
whether one or two copies of  a specific haplotype were as-
sociated with a particular therapy outcome compared to the 
GR wild-type carriers. If  the number of  subjects per group 
was large enough, heterozygous carriers with one wild-type 
allele and homozygous carriers of  one distinct haplotype 
were analyzed together against homozygous wild-type car-
riers. The latter calculations were only performed for haplo-
types which occurred in a reasonably large (> 40) number. 
The statistical analysis was performed using the software 
package SPSS 17 (SPSS Inc., Chicago, IL).
RESULTS
NR3C1 sequence variability
DNA samples from 185 IBD patients (CD or UC) were 
initially sequenced for the NR3C1 coding exons 2 to 9 
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Table 1  Oligonucleotides used as polymerase chain reaction primers to amplify the NR3C1 exons
Primer name Primer sequence Nested PCR Primer name Primer sequence
GR 2_F CACTTAGGTTGTCTACCTTTCCTAC Y GR 2_Fa TTCAAAAGGCCACTTAAACTTATTC
GR 2_R GATAGAAACTACTCTTCTGGTAAC Y GR 2_Ra CCTTGGAGATCAGACCTGTTG
Y GR 2_Fb CTGTGCCCAGTTTCTCTTGC
Y GR 2_Rb CAGCCAGATCTGTCCAAAGC
Y GR 2_Fc TTGGAAACTCCTTCTCTGTGG
Y GR 2_Rc AATGTGGCATGCTGAATGG
GR 3_F CATTAGAGGACCTAGGAGCCAC N
GR 3_R GAAGTGAACCAGAACCACACC N
GR 4_F TGAATTCAGTGTGTGTAAGAAGAAC N
GR 4_R TTGCACTGTTTTCAGTTTGTTG N
GR 5_F CACCTGTATTCACCTGACTCTCC N
GR 5_R TTTTTTCTCCTTTTCCATGTCAC N
GR 6_F GCCCCAAGCACTCATAACTC N
GR 6_R TCAGATGACAGAAGAAAACTGTGTC N
GR 7_F AATCTTGGTGTCACTTACTGTGC N
GR 7_R CCAAGATGCAGGAAGTTTAAGG N
GR 8_F CACCAACATCCACAAACTGG Y GR 8_Fa TTGGTCAGTGGGAACATC
GR 8_R CCACCAGTTCTTCTTACACACAC Y GR 8_Ra ATGGTGGCTTGTGCCTAC
GR 9a_F TGATGACGACTCAACTGCTTC N
GR 9a_R ATCTGGGGAATTCCAGTGAG N
GR 9b_F TCCTAAAAGGGCACAGCTTC N
GR 9b_R CAATCATTTGCTTTTTGAATGC N
PCR: Polymerase chain reaction; GR: Glucocorticoid receptor.
Table 2  Predicted haplotypes found to be in best reconstruction for 181 inflammatory bowel diseases patients
Haplotype 
number1
Haplotype composition2 Absolute haplotype frequency Relative haplotype 
frequency
Number of haplotypes 
not included3Reference: GGGATGGCCATGT (n  = 362)
GR_1 1111111111111 165 0.456
GR_24 1111112111211 90 0.249
GR_34 1111211111111 72 0.199 2
GR_44 1112111111111 8 0.022
GR_5 2211112111221 6 0.017
GR_6 1111112111212 4 0.011
GR_7 1111112111111 3 0.008
GR_8 1111111111211 2 0.006 1
GR_9 1111112121212 2 0.006
GR_10 1111221111111 2 0.006 2
GR_11 2211112111211 2 0.006 1
GR_12 1111111111212 1 0.003 1
GR_13 1111112211212 1 0.003
GR_14 1111211112111 1 0.003
GR_15 1111212111111 1 0.003
GR_16 1121111111111 1 0.003
GR_17 2211111111111 1 0.003 1
1Haplotypes are arranged in the order of decreasing frequency; 21 indicates the reference allele at a certain position, 2 indicates the 
variant allele; 3Number of haplotypes not included in the subsequent association analysis (steroid therapy outcome, tables 4, 7 and 8) 
due to likelihood values ≤ 0.95; 4Haplotype GR_2 corresponds to haplotype b, GR_3 corresponds to haplotype c and GR_4 corresponds 
to haplotype d in Figure 2. 
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and 50 bp of  the neighbouring intronic sequences. The 
sequencing results of  181 individuals were of  adequate 
quality and further used for SNP and haplotype analyses. 
The sequence data were screened for genetic variations 
in the NR3C1 gene, using the Basic Local Alignment 
Search Tool (BLAST; www.ncbi.nih.gov) and the Gen-
Bank entry NT_029289 as the reference sequence. 
In Table 3 we list the allele frequencies of  all detected 
SNPs within the IBD cohort under study. Thirteen vari-
ants were detected, which were-with exception of  one 
mutation (rs6196, P < 0.01)-in Hardy-Weinberg equilib-
rium. All variants were single nucleotide substitutions. 
Six variants were detected within the intronic regions, 
whereas seven variants were found in exons (Figure 1). 
Three of  the seven variants detected within the coding 
regions of  the NR3C1 gene resulted in non-synonymous 
amino acid exchanges, while four of  them did not lead 
to changes in the GR amino acid sequence. Eight vari-
ants occurred with an allelic frequency of  more than one 
percent (rs56149945, rs6189, rs6190, rs4986593, rs6188, 
rs258750, rs10482704, rs6196). All non-synonymous ami-
no acid exchanges (R23K, A229T, N363S) were found 
in the N-terminal half  of  GR, flanking the N-terminal 
transactivation domain[14]. The intronic variant found at 
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Table 3  Frequencies of single nucleotide polymorphisms detected in the glucocorticoid receptor gene (NR3C1)
SNP 
number
Alternative
name1
Variant              
number2
DNA 
position3
DNA 
region
cDNA      
position4
Nucleotide 
reference
Nucleotide 
variant
Amino acid 
exchange
Allele frequency
(n  = 362)
Reported allele 
frequencies2
1 2.1 rs6189 3943266 Exon 2   558 G A E22E 0.025 0.002-0.034
2 2.2 rs6190 3943264 Exon 2   560 G A R23K 0.025 0.002-0.034
3 2.3 rs72542742 3942647 Exon 2 1177 G A A229T 0.003 0.002
4 2.4 rs56149945 3942244 Exon 2 1580 A G N363S 0.025 0.000-0.046
5 3.1 rs4986593 3856773 Intron 3 T C 0.213 0.008-0.228
6 4.1 rs61753484 3852751 Intron 4 G C 0.006 0.000-0.009
7 5.1 rs6188 3843271 Intron 5 G T 0.290 0.000-0.500
8 6.1 rs6194 3841288 Exon 6 2256 C T H588H 0.006 0.000-0.091
9 8.1 rs258751 3825207 Exon 8 2526 C T D678D 0.006 0.000-0.149
10 8.2 novel SNP 3824968 Intron 8 A G 0.003 NA
11 8.3 rs258750 3824816 Intron 8 T C 0.307 0.091-0.362
12 8.4 rs10482704 3824690 Intron 8 G T 0.017 0.000-0.027
13 9.1 rs6196 3824417 Exon 9 2790 T C N766N 0.022 0.058-0.325
1Defines both the exon/intron localization and the single nucleotide polymorphism (SNP) number; 2According to the National Center for Biotechnology 
Information (NCBI) SNP database; 3According to the NCBI genomic reference sequence NT_029289.11; 4According to the NCBI cDNA reference cDNA 
Sequence NM_000176.2. NA: Not applicable.
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Figure 1  Most frequently occurring NR3C1 haplotypes and their single nucleotide polymorphisms composition. The localization of the variant nucleotides in 
the N3RC1 gene is indicated. All detected non-synonymous single nucleotide polymorphism (SNP) (R23K, A229T, N363S) flank the N-terminal transactivation domain. 
Only four out of 17 predicted haplotypes occur at a frequency higher than 2%.
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DNA position 3824968 has not been previously listed in 
the NCBI SNP database.
Haplotype analysis
The 13 NR3C1 variants described above were included in 
the haplotype calculations using the computer program 
PHASE. All 181 individuals were included in the haplo-
type prediction analysis (Figure 2). Twenty-five NR3C1 
haplotypes were predicted by PHASE to exist in the 
studied cohort. Furthermore, PHASE determined 17 dif-
ferent distinct haplotypes, which were found to be in best 
reconstruction for the cohort (Table 2). Six out of  these 
17 haplotypes occurred at a frequency higher than 1% 
(Figure 1). PHASE was only able to determine the haplo-
type structure of  174 individuals out of  181 subjects with 
a certainty of  ≥ 95%. The data of  one individual were 
excluded because of  missing demographic data. Thus, the 
predicted haplotypes of  173 individuals were included in 
the subsequent association analysis.
The two SNPs E22E/R23K were found to be in com-
plete linkage disequilibrium (Figure 3). This finding is in 
agreement with previous publications[15,16]. Furthermore, 
a strong but not complete linkage was found between the 
SNPs rs6188 and rs258750 (Figure 3). 
Analysis of NR3C1 haplotypes in relation to steroid 
therapy outcome
An overview of  the demographic data of  the 173 subjects 
included in the association analysis is shown in Table 4 
(further patient data on comedications and extraintestinal 
manifestations are given in Tables 5 and 6), and the hap-
lotype combinations calculated for all patients are shown 
in Table 7. As the numbers of  homozygous carriers of  
variant NR3C1 haplotypes were low, the subjects were 
analyzed as carriers of  one or two copies of  a distinct 
variant haplotype, irrespective of  whether the other allele 
was determined to be wild-type or variant in the case of  
heterozygotes (Table 8). Furthermore, haplotypes GR_2 
and GR_3 were analyzed by testing the heterozygous al-
lele combinations GR_2 + GR_1 (wt) together with the 
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Figure 3  Linkage disequilibrium calculations of single nucleotide poly-
morphisms in the NR3C1 gene. Linkage disequilibrium plot of r2 values of 
observed variants in the N3RC1 gene. Colour scheme: r2 = 0%, white, 0% < r2 < 
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Table 4  Demographic data of 173 inflammatory bowel diseases 
patients included in the association analysis
Characteristics Crohn’s disease Ulcerative colitis All
Patients 84 (49%) 89 (51%) 173 (100%)
Age (documented for 
171 individuals)
37.5 (± 15.3) 41.7 (± 14.2) 39.7 (± 14.9)
   mean ± SD 35 42   39
   Median 16 18   16
   Minimum 72 82   82
   Maximum
Known GC treatment 
outcome in the past
50 50 100
No. of patients currently 
treated with GCs
83 60 143
Male/female   52 (58.4%)/   40 (47.6%)/   92 (53.2%)/
37 (41.6%) 44 (52.4%) 81 (46.8%)
Wild-type carriers 15 (16.9%) 20 (23.8%) 35 (20.2%)
Carriers of one variant 
haplotype
48 (53.9%) 39 (46.4%) 87 (50.3%)
Carriers of two variant 
haplotypes
26 (29.2%) 25 (29.8%) 51 (29.5%)
Mwinyi J et al . GR haplotypes and IBD
GCs: Glucocorticoids.
homozygous GR_2 subjects and the allele combination 
GR_3 + GR_1 (wt) together with homozygous GR_3 
carriers against wild-type carriers. For all individuals, prior 
success of  GC therapy was documented, and for patients 
under GC therapy at the point of  study entry the applied 
dosage was also noted. 
No significant associations were observed between hap-
lotype GR_2 and success of  GC therapy (Figure 4). Upon 
stratification of  the patient cohort according to gender or 
disease subgroup (UC or CD), no significant association 
between therapy success or haplotype GR_2 was observed 
either. Similarly, when stratifying according to the subgroup 
of  heterozygous GR_2 + GR_1 and homozygous GR_2, 
no statistically significant difference in therapy response 
compared to wild-type carriers could be observed. 
No significant associations were observed between 
either haplotype GR_3 (Figure 5) or GR_4 (Table 8) and 
GC therapy outcome, or between individual SNPs and 
therapy success (Figure 6). Similarly, we observed no sig-
nificant associations between the severity of  disease (ac-
tive or inactive state of  UC or CD) or currently taken GC 
dose levels and NR3C1 haplotypes (data not shown).
DISCUSSION
Glucocorticoid receptor (GR) plays an important role in 
many physiological and pathological processes and is the 
main target of  glucocorticoids, widely used as therapeutic 
agents to treat a variety of  autoimmune diseases[8,17]. Two 
GR isoforms, GRα and GRb, generated by alternative 
mRNA splicing exist[18]. Only GRα can be activated by 
glucocorticoid ligands, while GRb does not bind gluco-
corticoids and may in fact act as an inhibitor of  gluco-
corticoid action[19]. Genetic variation in the NR3C1 gene 
has been shown to affect both disease pathophysiology 
and response to glucocorticoid therapy[15,20-22], suggesting 
that SNPs might play a role in GR function and associ-
ated steroid therapy outcome also in IBD patients. GR is 
known to regulate the intestinal bile acid uptake transport-
er ASBT[23,24], the expression of  which is altered in IBD 
patients[25]. While it has been reported that GR mRNA 
expression levels are not predictors of  steroid response in 
IBD[26] and that the GR polymorphisms R23K and N363S 
are not associated with CD in a pediatric Caucasian popu-
lation[27], no studies on the role of  NR3C1 gene variants in 
steroid therapy success were previously available. The aim 
of  the current study was to analyze sequence variation and 
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Table 5  Past and current additional medication of 173 in-
flammatory bowel diseases patients included in the association 
analysis 
Additional medication n
5-Aminosalicylic acid 142
6-Mercaptopurine 33
Adalimumab 3
Antibiotics 64
Azathioprine 122
Bisphosphonates 8
Certulizumab 1
Cholestyramine 8
Cyclosporine 8
Infliximab 45
Methotrexate 27
Sulfasalazine 12
Ursodeoxycholic acid 3
Table 6  Extraintestinal manifestations
Extraintestinal manifestations n  (%)1
Peripheral arthritis   46 (27.2)
Uveitis/iritis   6 (3.6)
Pyoderma gangrenosum   4 (2.4)
Erythema nodosum   9 (5.3)
Aphthous oral ulcers 10 (5.9)
Ankylosing spondylitis   7 (4.1)
Primary sclerosing cholangitis   6 (3.6)
1Documented for 169 patients.
Table 7  Predicted frequencies of haplotype combinations in 
173 inflammatory bowel diseases patients
Haplotype combination n Frequency
GR_1 + GR_2 or GR_2 hom 51 0.295
GR_1 + GR_3 or GR_3 hom 41 0.237
GR_1 hom (wt) 36 0.208
GR_2 + GR_3 23 0.133
GR_1 + GR_4 or GR_4 hom   6 0.035
GR_1 + GR_5   3 0.017
GR_3 + GR_6   2 0.012
GR_1 + GR_7 or GR_7 hom   1 0.006
GR_1 + GR_16 or GR_16 hom   1 0.006
GR_2 + GR_8   1 0.006
GR_2 + GR_6   1 0.006
GR_2 + GR_9   1 0.006
GR_6 + GR_13   1 0.006
GR_7 + GR_15   1 0.006
GR_2 + GR_4   1 0.006
GR_2 + GR_11   1 0.006
GR_5 + GR_9   1 0.006
GR_9 + GR_17   1 0.006
Table 8  Association between glucocorticoids therapy out-
come and the haplotype GR_4
Haplotype Cohort
composition
Therapy 
success 
rate 
in wt 
carriers 
(success/
no 
success)
Therapy 
success 
rate in 
het/hom 
variant 
carriers 
(success/ 
no success)
P -value OR (CI)
GR_4  
merged
All 0.682 
(15/7)
  0.4 (2/3) 0.326 3.214 
(0.434-23.787)
Male 0.733 
(11/4) 
NA (0/0) NA NA
Female 0.571 
(4/3)
  0.4 (2/3) 1.000 2.000
(0.194-20.614)
NA: Not applicable (at least one cell box was counted as 0, OR and P not 
calculatable).
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haplotype structures in the coding parts of  the NR3C1 
gene in a cohort of  181 Swiss IBD patients. We investi-
gated whether NR3C1 genetic variants or haplotypes may 
influence steroid therapy outcome in IBD patients.
We identified 13 variants in this study, of  which 12 
had already been previously submitted to the NCBI SNP 
database. We calculated the corresponding haplotypes in 
the IBD patient cohort and studied the association of  the 
most prevalent SNP combinations with steroid therapy 
outcome, disease activity, and age of  disease onset. Several 
NR3C1 SNPs have been previously associated with altered 
disease susceptibility or risk of  disease progression in oth-
er autoimmune diseases, such as Guillain-Barré Syndrome 
or multiple sclerosis[15,20]. Most of  these studies only ana-
lyzed the impact of  a small number of  pre-defined SNPs, 
such as the BclI polymorphism or the E22E/R23K poly-
morphisms[15,20,21]. Few reports have been published on 
the potential influence of  NR3C1 SNPs on sensitivity to 
endogenous or exogenously given GCs[17,28], and only one 
significant association between the polymorphism E22E/
R23K and sensitivity to exogenously administered GCs in 
elderly Dutch people has been reported[22]. So far no large 
cohort studies have been reported in which the influence 
of  NR3C1 SNPs on GC therapy outcome in IBD patients 
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Haplotype Cohort 
composition
Therapy success rate 
in wt carriers (No. of 
success/no success)
Therapy success rate in 
het/hom variant carriers (No. 
of success/no success)
P -value OR (CI)
GR_2 merged All 0.682 (15/7) 0.837 (36/7) 0.204 0.417 (0.124-1.395)
Male 0.733 (11/4) 0.905 (19/2) 0.210 0.289 (0.045-1.846)
Female 0.571 (4/3) 0.773 (17/5) 0.357 0.392 (0.065-2.369)
CD 0.615 (8/5) 0.900 (18/2) 0.084 0.178 (0.028-1.118)
UC 0.778 (7/2) 0.783 (18/5) 1.000 0.972 (0.152-6.231)
GR_2 only All 0.682 (15/7) 0.862 (25/4) 0.173 0.343 (0.086-1.370)
Male 0.733 (11/4) 0.875 (14/2) 0.394 0.393 (0.060-2.554)
Female 0.571 (4/3) 0.846 (11/2) 0.290 0.242 (0.029-2.027)
  0           1                 10
Figure 4  Haplotype GR_2 and steroid therapy outcome. Odds ratios and confidence intervals for the number of GR_2 carriers vs wild-type carriers in the 
responder group compared with non-responders to glucocorticoid therapy. No significant associations were found. Statistical analysis was performed with Fisher’s 
exact test. OR: Odds ratio; CI: Confidence interval; CD: Crohn's disease; UC: Ulcerative colitis.
Mutation Therapy success rate in wt 
carriers (success/no success)
Therapy success rate in het/hom 
mutated carriers (success/no success)
P -value OR (CI)
E22E/R23K 0.774 (72/21) 0.571 (4/3) 0.354  2.571 (0.533-12.408)
N363S 0.777 (73/21) 0.500 (3/3) 0.148  3.476 (0.653-18.508)
rs4986593 0.746 (47/16) 0.784 (29/8) 0.670 0.810 (0.308-2.131)
rs6188 0.714 (35/14) 0.804 (41/10) 0.294 0.610 (0.241-1.543)
rs258750 0.694 (34/15) 0.824 (42/9) 0.129 0.486 (0.189-1.246)
rs10482704 0.760 (73/23) 0.750 (3/1) 1.000   1.058 (0.105-10.671)
  0  1 10            100
Figure 6  NR3C1 variants and their influence on steroid therapy outcome. Odds ratios and confidence intervals for carriers of six single nucleotide polymorphisms 
against wild-type carriers in the group of glucocorticoid (GC) responders compared with GC non-responders. No significant associations were found. Statistical analysis 
was performed using chi-square or Fisher’s exact test. 
Haplotype Cohort 
composition
Therapy success rate 
in wt carriers (No. of 
success/no success)
Therapy success rate in 
het/hom variant carriers (No. 
of success/no success)
P -value OR (CI)
GR_2 merged All 0.682 (15/7) 0.318 (28/5) 0.188 0.383 (0.103-1.415)
Male 0.733 (11/4) 0.913 (4/1) 0.342 0.250 (0.024-2.609)
Female 0.571 (4/3) 0.810 (17/4) 0.318 0.314 (0.049-1.998)
CD 0.615 (8/5) 0.917 (11/1) 0.160 0.145 (0.014-1.489)
UC 0.778 (7/2) 0.810 (17/4) 1.000 0.824 (0.122-5.573)
GR_2 only All 0.682 (15/7) 0.842 (16/3) 0.292 0.402 (0.087-1.846)
Male 0.733 (11/4) 1.000 (6/0) 0.281            NA
Female 0.571 (4/3) 0.769 (10/3) 0.613 0.400 (0.055-2.886)
  0           1                 10
Figure 5  Haplotype GR_3 and steroid therapy outcome. Odds ratios and confidence intervals for the number of GR_3 carriers vs wild-type carriers in the responder 
group of responders compared with non-responders to glucocorticoid therapy. No significant associations were found. Statistical analysis was performed using Fisher’s 
exact test. CD: Crohn's disease; UC: Ulcerative colitis; NA: Not applicable.
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has been investigated. Here, we describe five NR3C1 
haplotypes occurring at a frequency > 1% and analyze the 
potential association of  the three most common haplo-
types GR_2, GR_3 and GR_4 with GC therapy outcome 
in IBD patients. While a large number of  NR3C1 variants 
are already registered in the NCBI SNP database, we ob-
served only eight variants that occurred at a frequency > 
1%, and these were responsible for the composition of  a 
relatively small group of  commonly occuring haplotypes. 
The overall risk for a certain UC and/or CD activity state 
or for a different steroid therapy outcome was not altered 
in GR_2, GR_3 or GR_4 carriers, in comparison with the 
wild-type carriers. Furthermore, no significant associa-
tions were observed between individual SNPs and GC 
therapy success. In the case of  certain SNPs/haplotypes 
(e.g. GR_4, E22E/R23K), a larger cohort would have 
been preferable in order to obtain more reliable results, as 
these variants occurred quite rarely in our patient group. 
Similarly to our observations, Dekker et al[20] could not 
detect any associations between distinct haplotypes and 
SNPs in a Guillain-Barré Syndrome cohort treated with 
methylprednisolone, although the authors noted that their 
study group was too small to obtain statistically reliable 
results. It remains to be seen whether the rare GR variants 
present in our study cohort will show significant associa-
tions in larger cohorts of  IBD patients.
In conclusion, we have performed a comprehen-
sive study analyzing the role of  genetic variants in the 
NR3C1 gene in glucocorticoid sensitivity in a Swiss co-
hort of  IBD patients. We show that NR3C1 haplotypes 
are not a general modulating factor in glucocorticoid 
therapy outcome. 
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genetic variation in the NR3C1 gene encoding the glucocorticoid receptor (GR) 
may affect the response to glucocorticoids in IBD patients.
Innovations and breakthroughs
In this comprehensive genetic analysis, all coding exons and exon-intron junc-
tions of the NR3C1 gene were sequenced in 181 IBD patients, who had been 
treated with glucocorticoids and whose past responses to this treatment had been 
recorded. This is the first published study on the effects of genetic variation in GR 
on glucocorticoid therapy in IBD patients, in a modestly sized study cohort.
Applications
If significant associations between genetic GR variants and glucocorticoid 
therapy outcome had been observed, this could have allowed more considered 
design of the individual therapy options upon prior genotyping of the patients.
Terminology
The transcription factor of the steroid receptor family, GR, is proposed to be a 
major mediator of anti-inflammatory pathways elicited by therapeutically admin-
istered glucocorticoids.
Peer review
The genetic study investigates the predictive value of NR3C1 gene variants 
towards the clinical outcome of patients with Crohn’s disease and ulcerative 
colitis. Although the result of this study was negative, the study was meaningful 
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